JP Morgan Chase
QNCX icon

JP Morgan Chase’s Quince Therapeutics QNCX Stock Holding History

JP Morgan Chase’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$48 Hold
2
– – ﹤0.01% 7366
2025
Q4 		$1.57K Hold
2
– – ﹤0.01% 6980
2025
Q3 		$764 Hold
2
– – ﹤0.01% 7014
2025
Q2 		$774 Sell
2
-1
-33% -$229 ﹤0.01% 6650
2025
Q1 		$728 Hold
3
– – ﹤0.01% 6663
2024
Q4 		$1.02K Hold
3
– – ﹤0.01% 6730
2024
Q3 		$425 Buy
3
+1
+50% +$143 ﹤0.01% 6818
2024
Q2 		$352 Hold
2
– – ﹤0.01% 6723
2024
Q1 		$497 Hold
2
– – ﹤0.01% 6719
2023
Q4 		$492 Hold
2
– – ﹤0.01% 6927
2023
Q3 		$525 Hold
2
– – ﹤0.01% 6720
2023
Q2 		$706 Hold
2
– – ﹤0.01% 6506
2023
Q1 		$1K Hold
2
– – ﹤0.01% 6540
2022
Q4 		$0 Sell
2
-1,162
-100% -$194K ﹤0.01% 6911
2022
Q3 		$310K Sell
1,164
-1,671
-59% -$636K ﹤0.01% 4737
2022
Q2 		$1.26M Sell
2,835
-117
-4% -$82.7K ﹤0.01% 3910
2022
Q1 		$3.65M Buy
2,952
+2,901
+5,688% +$3.95M ﹤0.01% 3264
2021
Q4 		$128K Sell
51
-17
-25% -$104K ﹤0.01% 5576
2021
Q3 		$1.24M Buy
68
+7
+11% +$111K ﹤0.01% 4148
2021
Q2 		$645K Buy
61
+17
+39% +$143K ﹤0.01% 4543
2021
Q1 		$321K Sell
44
-42
-49% -$302K ﹤0.01% 4935
2020
Q4 		$477K Buy
86
+32
+59% +$284K ﹤0.01% 4394
2020
Q3 		$539K Buy
54
+2
+4% +$18.2K ﹤0.01% 3948
2020
Q2 		$481K Sell
52
-20
-28% -$183K ﹤0.01% 3870
2020
Q1 		$654K Buy
72
+12
+20% +$118K ﹤0.01% 3684
2019
Q4 		$673K Buy
60
+44
+275% +$265K ﹤0.01% 4088
2019
Q3 		$82K Buy
16
+6
+60% +$36.9K ﹤0.01% 4972
2019
Q2 		$78K Buy
+10
New +$59.7K ﹤0.01% 5014

Other funds holding QNCX

WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.5B AUM 75.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

JP Morgan Chase's QNCX Position: Q1 2026 in Review

JP Morgan Chase held its Quince Therapeutics (QNCX) position steady in Q1 2026 at 2 shares worth $48. The position accounts for ﹤0.01% of the portfolio, ranked #7366.

JP Morgan Chase first reported a position in QNCX in Q2 2019 and has held it in 28 quarters since. The position peaked at $3.65M in Q1 2022. 43 funds tracked by Wall St. Rank hold QNCX as of Q1 2026.

  • JP Morgan Chase held 2 shares of Quince Therapeutics worth $48 as of Q1 2026.
  • JP Morgan Chase left its Quince Therapeutics share count unchanged in Q1 2026.
  • Quince Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #7366 holding.
  • JP Morgan Chase first reported a position in Quince Therapeutics in Q2 2019 and has held it in 28 quarters since.
  • JP Morgan Chase's Quince Therapeutics position peaked at $3.65M in Q1 2022.
  • 43 funds tracked by Wall St. Rank held Quince Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.